[Amiodarone causes endothelium-dependent vasodilation in canine coronary arteries]

Alfredo José Rodrigues1, Paulo Roberto Barbosa Evora, Ayako Maruo

  • 1Faculdade de Medicina de Ribeirão Preto, USP, Ribeirão Preto, SP. alfredo@smnp.usp.br

Insights

Amiodarone causes vasodilation in canine coronary arteries by stimulating nitric oxide and cyclooxygenase-dependent factors. This effect is endothelium-dependent and more pronounced with polysorbate 80 or commercial formulations.

Area of Science:

  • Pharmacology
  • Cardiovascular Physiology

Context:

  • Amiodarone is an antiarrhythmic drug with potential vasodilatory effects.
  • Understanding amiodarone's impact on coronary arteries is crucial for cardiovascular health.
  • Canine coronary arteries serve as a model for studying vascular responses.

Purpose:

  • To investigate the vasodilating effects of amiodarone on canine coronary arteries.
  • To compare the efficacy of amiodarone dissolved in polysorbate 80 versus water.
  • To elucidate the mechanisms underlying amiodarone-induced vasodilation.

Summary:

  • Amiodarone, particularly when dissolved in polysorbate 80 or as a commercial formulation (Cordarone), induced endothelium-dependent vasodilation in canine coronary arteries.
  • Polysorbate 80 alone caused minimal non-endothelium-dependent relaxation.
  • The vasodilation was primarily mediated by nitric oxide and cyclooxygenase-dependent pathways, as evidenced by the blockade of these effects with indomethacin and N-omega-nitro-L-arginine.

Impact:

  • Reveals amiodarone's vasodilatory properties in coronary circulation.
  • Highlights the role of the endothelium and specific signaling pathways in amiodarone's vascular effects.
  • Provides insights into formulation-dependent differences in amiodarone's pharmacological actions.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...